International Journal of Advanced Research in Engineering Technology & Science

ISSN: 2349-2819

Email: editor@ijarets.org Volume-9, Issue-7 July – 2022 www.ijarets.org

Experimental Pathway for the Synthesis of Sertraline: Effective Medicinal Agent

Mr. Vivek Malik
Research Scholar, Department of Chemistry, OPJS University,Rajasthan, India

Dr. Swapnila Roy
Associate Professor, Dept of Chemistry, OPJS University, Churu(Raj.)

Dr. K.P Malik
General Manager, Zydus Cadila,Vadodara, Gujrat,India

Abstract:

Sertraline hydrochloride, is a very effective antidepressant. Sertraline belongs to those medicinal agents having one or more asymmetric centers in which the isomers show significant differences in their biological activity. Sertraline hydrochloride [(+)-**1**] selectively blocks serotonine reuptake and is used for the treatment of depression, as well as dependency- and other anxiety-related disorders. In the synthesis of sertraline having two asymmetric centers, it would customarily be preferable to create the desired configurations as early as possible to minimize the loss generated from the unwanted isomer. This paper presents a novel industrial synthesis of sertraline hydrochloride that is in many respects more advantageous than processes reported thus far. *N*-[4-(3,4-Dichlorophenyl)-3,4-dihydro-1(2*H*)-naphthalenylidene]methanamine *N*-oxide is used as an intermediate in the process, which is a stable compound in normal conditions. Sertraline belongs to those medicinal agents having one or more asymmetric centers in which the isomers show significant differences in their biological activity,[3] and therefore, it is necessary to produce the biologically active 1*S*,4*S*-enantiomer, sertraline, with high optical purity. It can be obtained in a simple reaction from the corresponding tetralone in good yield, using acceptable reagents with regard to environmental and safety respects. Its reduction to the desired *cis*-racemic amine is stereoselective, and thus it provides sertraline hydrochloride with the purity required for pharmaceutical ingredients.

Keywords: Antidepressant, Sertraline hydrochloride, synthesis, tetralone, biological activity, medicinal agents

1. Introduction

Sertraline hydrochloride [(+)-**1**] selectively blocks serotonine reuptake and is used for the treatment of depression, as well as dependency- and other anxiety-related disorders[**1-5**].

Sertraline belongs to those medicinal agents having one or more asymmetric centers in which the isomers show significant differences in their biological activity[**6-10**], and therefore, it is necessary to produce the biologically active 1*S*,4*S*-enantiomer, sertraline, with high optical purity (**Figure 1**).

2. Experimental Methodology:

Solvents and reagents were obtained from commercial sources[**11-13**]. NMR spectra were recorded on a spectrometer (H: 300 MHz) using $CDCl_3$ as a solvent, temperature: 24 °C, reference: δ_{TMS}) 0.00 ppm. MS spectra were obtained using a VG-TRIO-2 -spectrometer, ionization mode: EI, electron energy: 70 eV, ion source temperature: 250 °C. Infrared data were recorded on a spectrophotometer, phase: KBr pellet, resolution: 4 cm^{-1}. Melting points were determined on the melting point apparatus.

- **4-(3,4-Dichlorophenyl)-3,4-dihydro-2*H*-naphthalen-1one :**

  To a stirred solution of 1-naphthol (0.15 mol) in 1,2-dichlorobenzene (140 mL) anhydrous $AlCl_3$ (0.375 mol) was added. The reaction mixture was heated to 100 °C and stirred at this temperature for 1 h. The mixture was then cooled to room temperature and poured into ice (240 g) and concentrated hydrochloric acid (70 mL), followed by the addition of CH_2Cl_2 (200 mL). The organic layer was separated, and the aqueous layer was extracted twice with CH_2Cl_2 (50 mL). The combined organic layers were washed with water (200 mL) and stirred with Celite (20 g) and activated carbon (10 g) and filtered; the solvents were then evaporated in a vacuum. To the oily residue (45-50 g) methanol (44 mL) was added. The product was crystallized, filtered, and then washed twice with methanol. Yield: 80%. Mp: 98-101 °C.

- **4-(3,4-Dichlorophenyl)-3,4-dihydro-2*H*-naphthalen-1one Oxime:**

  Tetralone(0.01 mol), hydroxylamine hydrochloride (0.05 mol) and NaOAc (0.05 mol) were suspended in a mixture of ethanol (60 mL) and water (24 mL). The reaction mixture was stirred under reflux for 4 h. After cooling to room-temperature water (36 mL) was added. The precipitated product was filtered and washed with water. Yield: 97%. Mp.: 159 -162°C.

- ***N*-[4-(3,4-Dichlorophenyl)-3,4-dihydro-1(2*H*)-naphthalenylidene]-methanamine *N*-Oxide:**

  Tetralone(0.158 mol), *N*-methylhydroxylamine hydrochloride (0.317 mol), and anhydrous NaOAc (0.317 mol) in ethanol (600 mL) were stirred and heated until boiling. After 6 h heating under reflux, the ethanol was evaporated in a vacuum. To the residue, water (200 mL) and CH_2Cl_2 (200 mL) were added. The aqueous layer was washed with CH_2Cl_2 (100 mL), and then the combined organic layers were extracted with water (100 mL). The organic layer was dried over anhydrous Na_2SO_4 and filtered, and the solvent was evaporated in a vacuum.

- ***cis*-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-*N*-methyl-1-naphthalenamine Hydrochloride [(()-1]:**

Nitrone(11.2 g, 35 mmol) was suspended in methanol (200 mL) and hydrogenated over Raney-nickel catalyst (3-4 g),and washed to pH neutral at atmospheric pressure and 25 °C. After the theoretical hydrogen uptake had ceased (5-6 h), the catalyst was filtered, and the methanol was evaporated. The residue was dissolved in ethanol (60 mL), then 6.8 M HCl in ethanol (5.1 mL) was added dropwise to the stirred solution. The product was filtered and washed with ethanol. Yield: 82% of the title compound. Mp: 289-291 °C.

- **(*cis*-1*S*)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-*N*-*methyl*-1-naphthalenamine Hydrochloride (Sertraline Hydrochloride) [(+)-1]:**

  Cis-racemic amine hydrochloride (()-**1** (30 mmol) was suspended in CH_2Cl_2 (70 mL) and extracted with 10% aqueous Na_2CO_3 (40 mL). The aqueous layer was extracted with CH_2Cl_2 (30 mL), and then the combined organic layers were dried over Na_2SO_4 and filtered. The solvent was evaporated in a vacuum. The residue was then dissolved in ethanol (100 mL), and *R*-(-)-mandelic acid (30 mol) was added. The mandelic acid salt crystallized after a few minutes. The resulting suspension was stirred for 6 h at 25 °C and then filtered and washed with ethanol (50 mL). (*cis*-1*S*)-4-(3,4-Dichlorophenyl)1,2,3,4-tetrahydro-*N*-methyl-1-naphthalenamine (*R*)-mandelate (40%) was obtained. Mp: 189-191 °C.

The above-described mandelic acid salt (5g, 11 mmol) was mixed with CH_2Cl_2 (50 mL) and 2 M aqueous NaOH (30 mL). The layers were separated, and the aqueous layer was extracted with CH_2Cl_2 (20 mL). The combined organic layers were dried over Na_2SO_4 and filtered, and the solvent was evaporated in a vacuum. The residue was dissolved in ethanol (30 mL), and during stirring 6.8 M HCl in ethanol (1.62 mL) was added. The precipitated product was filtered and washed with ethanol. Yield:83%. Mp: 246249 °C. $[R]^{25}_{D}$)+38.9 (*c*) 2, methanol).

3. Results and Discussion

The key intermediate of the previous syntheses of sertraline was tetralone. In the original synthesis, this compound was obtained in five steps, by classical reactions with a low overall yield[**14-19**]. Tetralone was then reacted with 7 equivalent of methylamine in the presence of $TiCl_4$ as a catalyst, and the corresponding Schiff base was formed. $TiCl_4$ is an extremely corrosive material, that requires special treatment during the reaction, and after workup, a large amount of hazardous material is formed. In an improved version,$TiCl_4$ was replaced by molecular sieves, but in this case, 17 equivalent of methylamine was needed to achieve an acceptable yield. The latter reagent is a registered carcinogen, and protection against it is especially difficult because it is a gaseous material**[20-22**]. The subsequent reduction of the Schiff base resulted in a mixture of amines, ()-**1** and ()-**3**, from which the useful *cis*-isomer was separated by crystallization as its hydrochloride salt. Using $NaBH_4$ as a reducing agent the ratio of

cis/*trans* isomers was 1:1, which was increased to 7.2:3.4 by catalytic hydrogenation on Pd/C. In the latter case, the primary yield of (()-**1** was ~50%. After the workup of the mother liquor, a second crop was obtained, and the total yield was increased to ~70%. Finally, resolution of (()-**1** with *R*-(-)-mandelic acid provided the 1*S*,4*S*-isomer [(+)-**1**], which is the required active ingredient (Scheme 1).

In the synthesis of sertraline having two asymmetric centers, it would customarily be preferable to create the desired configurations as early as possible. Although enantioselective syntheses of the required (*S*)-enantiomer of tetralonehave been achieved. On the other hand, the improvement of the synthesis of racemic tetralone was so successful with this simple industrial procedure(Scheme 2).

Our conversion of tetralone to sertraline sought to improve upon the 3:1.1 *cis*/*trans* selectivity reported for the reduction of the *N*-methylimine,and avoid the use of unacceptable reagents from the environmental and safety aspects ($TiCl_4$ and excess methylamine, respectively).

The oxo compounds can easily be converted to oximes or nitrones with hydroxylamines, after which they can then be reduced to primary or secondary amines, respectively. Indeed, tetralone easily forms the corresponding oxime by reaction with hydroxylamine. However, conversion of sertraline requires selective monomethylation of amine, which may cause difficulties. Condensation of tetralin with *N*-methyl hydroxylamine results in nitrone, whose reduction directly leads to amines. During the formation of nitronegeometric isomerism takes place. In the reaction mixture, the *E*/*Z* isomers are in equilibrium with each other, with an approximate ratio of 3:2. However, the isolation procedure provides only the thermodynamically more stable *Z* isomer.

The use of the above-mentioned nitrone intermediate offers many advantages over the corresponding Schiff base applied in the previously known syntheses of sertraline**[23-25**]. The reagent *N*-methyl hydroxylamine hydrochloride is solid, easily treatable, and only 2 equivalent of excess is needed in the reaction. Furthermore, there is no data on its possible carcinogenic or other toxic effects. Nitrone obtained as described above can be isolated in stable crystalline form. After keeping it for months at room temperature, only slight coloration was observed.

The use of nitrone was successful with respect to reduction as well. Reduction with $NaBH_4$ is partial, providing mainly the corresponding hydroxylamine. Catalytic hydrogenation on palladium-containing catalysts, even in deactivated cases, resulted in partial dehalogenation, which was reflected in the low yields as well (entries 1-3, Table 1). Hydrogenation on PtO_2 was not at all selective (entry 4, Table 1).

Using Raney-Ni as catalyst (entry 5, Table 1), a 92:8 *cis*/*trans* ratio was achieved, as determined by HPLC, and the *cis*-racemic amine hydrochloride (()-**1** was isolated in 81% yield. Sertraline with the

required purity was obtained according to the literature by resolution of (()-**1** with *R*-(-)-mandelic acid and then hydrogen chloride salt formation.



Figure 1.

Scheme 1:-



Scheme 2:-



Table 1.Summary of reductions of nitrone

Entry	catalyst	yield of ()-**1 (%)**	ratio of *cis*/*trans* isomers
1	Pd/C55	85:15	
2	$Pd/CaCO_3$	52	86:14
3	$Pd/BaSO_4$	55	85:15
4	PtO_2 69	60:40	
5	Raney Ni	59	92:8

Raney-Ni as catalyst (entry 5, Table 1), a 92:8 *cis*/*trans* ratio was achieved, as determined by HPLC, and the *cis*-racemic amine hydrochloride ()-**1** was isolated in 81% yield. Sertraline with the required purity was obtained according to the literature by resolution of ()-**1** with *R*-(-)-mandelic acid and then hydrogen chloride salt formation. This synthesis is described in our patent.

4. Acknowledgment

I wish to record my deep sense of gratitude and profound thanks to my teacher and research guide Dr. Swapnila Roy and Dr. K.P Malik for their guidance, constant encouragement, and valuable suggestions throughout this course. I am very thankful for his unflinching support, and affection, which helped me a lot in exploring my abilities and made it possible for me to carry out the present work which otherwise, would be very difficult.

5.References:

1. Wang JH, Liu ZQ, Wang W, Chen XP, Shu Y, He N, Zhou HH (2001). "Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19". Clin. Pharmacol. Ther. 70 (1): 42–7. doi:10.1067/mcp.2001.116513. PMID 11452243

2. Hamelin BA, Turgeon J, Vallée F, Bélanger PM, Paquet F, LeBel M (1996). "The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin". Clin. Pharmacol. Ther. 60 (5): 512–21. doi:10.1016/S0009-9236(96)90147-2. PMID 8941024.

3. Kobayashi K, Ishizuka T, Shimada N, Yoshimura Y, Kamijima K, Chiba K (1999). "Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro". Drug Metab. Dispos. 27 (7): 763–6. PMID 10383917.

4. Young TJ, Oliver GP, Pryde D, Perros M, Parkinson T (April 2003). "Antifungal activity of selective serotonin reuptake inhibitors attributed to non-specific cytotoxicity". Journal of Antimicrobial Chemotherapy 51 (4): 1045–1047. doi:10.1093/jac/dkg184. PMID 12654745.

5. Gobin V, Van Steendam K, Denys D, Deforce D (2014) Selective serotonin reuptake inhibitors as a novel class of immunosuppressants. Int Immunopharmacol 20: 148-156.

6. Ashbury JE, Lévesque LE, Beck PA, Aronson KJ (2012) Selective serotonin reuptake inhibitor (SSRI) antidepressants, prolactin and breast cancer. Front Oncol 2: 177.

7. Pohl RB, Wolkow RM, Clary CM (1998) Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatr 155: 1189-1195.

8. Katzelnick DI, Kobak KA, Greist JH, Jefferson JW, Mantle JM, et al. (1995) Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatr 152: 1368-1371.

9. Greist JH, Jefferson JW, Kobak KA, Chouinard G, DuBoff E, et al. (1995) A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 10: 57-66.

10. Ventimiglia J, Kalali AH (2010) Generic penetration in the retail antidepressant market. Psychiatry (Edgmont) 7: 9-11.

11. The United State Pharmacopoeia (2016) Sertraline Hydrochloride Monograph. 3: 5831-5833.

12. European Pharmacopoeia (2011) Sertraline Hydrochloride Monograph 1705.

3: 3210-3212.

13. ICH (2006) Impurities in New Drug Substances Q3A (R2). International conference on harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.

14. Rogowsky D, Marr M, Long G, Moore C (1994) Determination of sertraline and desmethylsertraline in human serum using copolymeric bonded-phase extraction, liquid chromatography and gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 655: 138-141.

15. Kim KM, Jung BH, Choi MH, Woo JS, Paeng KJ, et al. (2002) Rapid and sensitive determination of sertraline in human plasma using gas chromatography-mass spectrometry. J Chromatogr B 769: 333-339.

16. Tournel G, Houdret N, Hedouin V, Deveaux M, Gosset D, et al. (2001) High performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum. J Chromatogr B Biomed Sci Appl 761: 147-158.

17. Hashimoto, K (2009). "Sigma-1 Receptors and Selective Serotonin Reuptake Inhibitors: Clinical Implications of their Relationship". Central Nervous System Agents in Medicinal Chemistry 2009 (Sept): 197–204.

18. Narita N, Hashimoto K, Tomitaka S, Minabe Y (1996). "Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain". Eur. J. Pharmacol. 307 (1): 117–9. doi:10.1016/0014-2999(96)00254-3. PMID 8831113.

19. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004). "Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study". The American Journal of Psychiatry 161 (5): 826–35. doi:10.1176/appi.ajp.161.5.826. PMID 15121647.

20. Allard S, Sainati SM, Roth-Schechter BF (1999). "Coadministration of short-term zolpidem with sertraline in healthy women". Journal of clinical pharmacology 39 (2): 184–91. doi:10.1177/00912709922007624. PMID 11563412.

21. Adderall XR Prescribing Information". Medication Guide. United States Food and Drug Administration.

22. Thomas E. Brown; Thomas E. Brown (Ph. D.) (2009). ADHD comorbidities: handbook for ADHD complications in children and adults. American Psychiatric Pub. ISBN 978-1-58562-158-3.

23. Preskorn SH, Greenblatt DJ, Flockhart D, Luo Y, Perloff ES, Harmatz JS, Baker B, Klick-Davis A, Desta Z, Burt T (2007). "Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers". Journal of Clinical Psychopharmacology 27 (1): 28–34. doi:10.1097/00004714-200702000-00005. PMID 17224709.

24. Alfaro CL, Lam YW, Simpson J, Ereshefsky L (1999). "CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline". Journal of Clinical Psychopharmacology 19 (2): 155–63. doi:10.1097/00004714-199904000-00011. PMID 10211917

25. Amsden GW, Georgian F (1996). "Orthostatic hypotension induced by sertraline withdrawal". Pharmacotherapy 16 (4): 684–6. PMID 8840377.